Welcome to our dedicated page for Nkarta news (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta stock.
Nkarta, Inc. reports developments as a clinical-stage biotechnology company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for autoimmune diseases. Company updates center on NKX019, an investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases, and on the Ntrust-1 and Ntrust-2 clinical studies.
Recurring news themes include FDA protocol discussions, outpatient dosing plans, dose-escalation updates, B-cell depletion data, preclinical and clinical presentations, quarterly financial results, cash runway commentary, workforce and operating updates, and participation in healthcare and investor conferences.
Nkarta (NKTX) will participate in two investor conferences in September 2026, each featuring a fireside chat.
The company is scheduled for the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 16, 2026, at 10:30 a.m. ET and the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026, at 12:30 p.m. ET. Webcasts and replays of both events will be available in the Investors section of Nkarta’s website for approximately 90 days.
Nkarta (NKTX) will present initial autoimmune clinical data for its investigational CAR-NK therapy NKX019 at ACR Convergence 2026 in Orlando.
Three presentations were accepted: two oral talks on NKX019’s safety across autoimmune indications in the Ntrust Phase 1/2 studies and its clinical activity in idiopathic inflammatory myopathy, and a poster on preliminary safety, PK/PD and clinical activity in systemic sclerosis. The meeting runs November 6‑11, 2026.
The idiopathic inflammatory myopathy oral presentation (Abstract #0903) is scheduled for Sunday, November 8, 1:15–1:30 pm ET. A second oral talk on immune‑mediated and hematologic safety outcomes following lymphodepletion and NKX019 in B‑cell–mediated autoimmune diseases (Abstract #2938) is set for Wednesday, November 11, 10:15–10:30 am ET. The systemic sclerosis poster (Abstract #1179) will be presented Monday, November 9, 10:30 am–12:30 pm ET.
The Ntrust-1 and Ntrust-2 basket trials are multicenter, open‑label, dose‑escalation studies enrolling up to 12 patients per dose level per indication across several B‑cell–driven autoimmune diseases, evaluating NKX019 after fludarabine/cyclophosphamide or cyclophosphamide-only lymphodepletion. Presentation materials are expected to be posted on Nkarta’s website following the event.
Nkarta (Nasdaq: NKTX) reported second quarter 2026 results, highlighting continued enrollment in its Ntrust-1 and Ntrust-2 trials of NKX019 across multiple autoimmune diseases at a 4 billion cell dose per infusion, given as a three-dose 12 billion cell cycle in the outpatient setting.
Outpatient dosing is underway at community-based sites, with the option for additional NKX019 cycles if needed, and initial clinical data are planned for presentation at a medical conference in 2026. Nkarta reported $243.2 million in cash, cash equivalents, restricted cash and marketable securities at June 30, 2026, and expects this to fund its current operating plan into 2029. Second quarter 2026 R&D expense was $29.0 million, G&A expense was $14.1 million, and net loss was $40.4 million, or $0.54 per share, including $11.8 million of non-cash charges.
Nkarta (Nasdaq:NKTX), a clinical-stage biopharma developing engineered NK cell therapies for autoimmune diseases, will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.
On June 30 at 2 p.m. ET, President Nadir Mahmood will join a webcast fireside chat on Nkarta’s investigational CAR-NK therapy for B cell-mediated autoimmune diseases, with a replay available for about 90 days.
Nkarta (Nasdaq:NKTX) reported first quarter 2026 results and NKX019 clinical progress. Cash, cash equivalents and investments were $266.7 million on March 31, 2026, with funding expected to support operations into 2029.
Enrollment continues in Ntrust-1 and Ntrust-2 at a 4 billion cell NKX019 dose, with protocol changes enabling outpatient dosing and rheumatoid arthritis patients. Initial clinical data are planned for presentation at a medical meeting in 2026. First quarter net loss was $27.8 million, or $0.37 per share.
Nkarta (Nasdaq: NKTX) reached agreement with the FDA to amend Ntrust-1 and Ntrust-2 protocols to permit outpatient dosing of NKX019, reducing post-dose monitoring from 24 hours to 2 hours.
The amendments also allow an option to re-dose, add a rheumatoid arthritis cohort to Ntrust-2, continue dosing at a 4 billion cell level (12 billion cells per three-dose cycle), and remove geographic monitoring requirements; initial data are expected at a medical meeting this year.
Nkarta (Nasdaq: NKTX) will participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. CEO Paul Hastings will join a panel at 11:45 a.m. ET on “Cell Therapy in Autoimmune.” President Nadir Mahmood will deliver a fireside chat at 3:45 p.m. ET covering updates on Nkarta’s investigational CAR-NK therapy for B cell-mediated autoimmune diseases. A simultaneous webcast of the fireside chat will be available on the company’s Investors website, with a replay archived for approximately 90 days.
Nkarta (Nasdaq: NKTX) reported fourth-quarter and full-year 2025 results and clinical progress on March 25, 2026. The company had $295.1 million of cash and investments as of December 31, 2025, which it says will fund operations into 2029. Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 (12 billion cells per cycle). Initial clinical data from Ntrust-1 and Ntrust-2 are targeted for presentation at a medical conference in 2026. Full-year R&D was $90.4 million and net loss was $104.1 million (or $1.41 per share).
Nkarta (Nasdaq: NKTX) will participate in two investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference on March 2, 2026 and the Leerink Global Healthcare Conference on March 10, 2026.
Each appearance is a fireside chat (9:10 a.m. EST on March 2; 10:40 a.m. EDT on March 10). A simultaneous webcast will be available on the company Investors site, with a replay archived for approximately 90 days.
Nkarta (Nasdaq: NKTX) will participate in the Evercore 8th Annual Healthcare Conference in Miami on December 4, 2025. Management will appear in a 10:50 a.m. ET fireside chat. A simultaneous webcast will be available on Nkarta’s Investors website, with a replay archived for approximately 90 days.
The presentation focuses on Nkarta’s clinical-stage engineered natural killer (NK) cell therapies for autoimmune diseases and provides an investor access point via live webcast and short-term replay.